Tergus is more than a team of people, it is a family. We believe in understanding each individual’s requirements and provide them with the opportunity to learn and grow. Employees are encouraged to engage in continuous learning and be ahead of the curve. Training is provided on a regular basis to facilitate professional growth. Our focus is to learn every day and produce quality work. In addition to maintaining strong technical acumen, Tergus peers guide each other every step of the way. We have key people in each business unit who work towards making Tergus a leader in topical product development.
Dr. Nalamothu is CEO & Co-Founder of Tergus Pharma and has been a leader in topical pharmaceutical development for more than two decades. He holds several patents and his efforts have led to a number of successful commercial products. His passion is to develop products that speak for themselves, leading him to be a co-founder of Tergus, shepherding the company to its industry-leading position in the marketplace.
After earning his Ph.D. in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly-owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization.
Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles, and accolades. He is a sought-after speaker at conferences worldwide.
Sr. Vice-President of Quality and Regulatory Compliance.
Mr. Burns joins Tergus after having spent the past twenty-seven years in various Quality and Regulatory positions in the pharmaceutical industry on both the development and commercial aspects of large and small pharma companies, including biologics, sterile injectable drugs, oral solid dosage forms, and medical devices. Alan brings a strong regulatory agency audit background, including inspections at worldwide locations, in addition to many others; experience also includes pre-clinical and clinical stage startup experience, clinical trial oversight, and CMO oversight.
Mr. Burns graduated from Arkansas State University with a B.S. degree in Zoology, a Master’s degree in Regulatory Affairs from San Diego State University, and the completion of an Executive Management program at Yale University.
Alon serves as a Skin Biology Scientist III with the responsibility of conducting various studies and developing novel assays using ex-vivo human skin models. Such experiments include validation of target engagement, skin irritation testing, effects on pigmentation and more. Alon brings over 13 years of practical knowledge of human skin structure, function, and pathology. His previous work in academic settings focused on the investigation of molecular processes that regulate human skin barrier, phototoxicity, inflammation, skin cancer, hair loss, and abnormal scars.
Prior to joining EnDev/Tergus, Alon received his training in skin biology at the department of dermatology at the University of Rochester, NY, and served as a Research Associate at Hampton University Skin of Color Research Institute in Virginia.
Alon earned a bachelor’s degree in Biotechnology Engineering in Israel and a Ph.D. in Pharmacology from the University of Rochester, NY. His work on human skin function and disease has been published in top journals and received several awards and recognition from his peers.
Avinash Mettu leads the Business Strategy and Business operations with Tergus Pharma. In this role,Avinash will be an integral part of key business initiatives by working with the core management teambesides leading process efficiencies/engineering, vendor relationships, capex & supply chain decisionmaking, M&A and financial analysis.
He holds a Bachelors in Electronics and Communications Engineering and an MBA from State Universityof New York. He started his career as an entrepreneur and worked on multiple management consultingassignments before joining Tergus as an Intern. He brings in strong analytical and enterprise levelthinking along with a tremendous thirst to learn that will ensure significant contribution towards Tergus’
In Bethany’s experience with Tergus Pharma, project management and workflow are the key components to leading the IVRT team. Working with the IVRT team has taught her how a successful group of people can work in concert with one another to achieve quality and compliance together.
With over 15 years of experience in Pharmaceutical Chemistry, Bethany began her career as a QC Chemist running stock methods for stock products in large Pharma. For the last 10 years, she has spent her career in CROs which lent her the ability to learn about and analyze multiple forms of pharmaceutical dosing.
James has worked in the pharmaceutical industry for 7 years and currently holds the position of Analytical Scientist II at the Kannapolis site. He primarily works on analytical method development and validation in support of formulation development projects. Prior to joining EnDev and Tergus James was a Team Leader in the Method Development and Validation group at Mayne Pharma in Greenville, NC. His focus there was supporting customer projects from early phase formulation development through to commercial manufacturing. A big emphasis in James’ time there was to develop phase appropriate approaches to method validation in order to streamline projects for our customers. Outside of work he enjoys running, mountain biking, skiing and travelling.
Dr. Thakker is Co-Founder Emeritus of Tergus and is a pioneer in functional testing for semi-solids. Under her leadership, Tergus has emerged as the recognized global leader in developing release rate methods for semi-solid dosage forms.
She was involved in the development of in Vitro Release Testing (IVRT), recognized as an essential testing protocol for Semi-solid dosage forms. Her work led to the development of the SUPAC-SS guidance document that the pharmaceutical industry follows. She was also a member of the USP’s Advisory Panel from 2010-2015, and helped draft chapters 3 and 1724, and also a member of USP’s Expert Committee on Dosage forms.
Dr. Thakker earned her PhD in Pharmaceutical Chemistry at the University of Kansas. She worked at US Pharmacopeia for 12 years, where she specialized in the development and validation of dissolution methods in the Drug Research and Testing Laboratory. Dr. Thakker has also held leadership positions at Sphinx Pharmaceuticals and BioAnalytika Laboratories.
With the emergence of newer, alternative dosage forms over the past 10 years, she has surfaced as a well-recognized global leader in the development of topical drug products, providing expertise in the development and validation of performance tests used to evaluate the transport of drugs across skin and other membranes (e.g., buccal, sublingual, vaginal, rectal). Working with compendial and regulatory organizations, Dr. Thakker continues to strive toward improving public standards for topical and other dosage forms.
Ravi leads a team of analytical scientists on multiple projects for providing pre-formulation/formulation support with studies including solubility, Drug-Excipient Compatibility, DOE, and prototype stabilities. He is an analytical point of contact for clients and represent the group in client meetings. He is very proficient in the development of stability-indicating HPLC methods, phase-appropriate validations, and method transfers to support topical drug product development. Apart from early R&D, his team occasionally provides support for GLP/GMP manufacturing campaigns with release and stability.
He has a Master’s degree in Pharmaceutical Sciences from Campbell University with a focus in Industrial Pharmacy. He was inducted in Rho-Chi Pharmaceutical Honor Society for his academic excellence. With his pharmaceutical background, he takes interest in formulation development as well.Outside work, Ravi is a foodie, plays ping-pong and an aspiring runner. He loves to travel and learn about different cultures.
Srikanth Manne works as Principal Scientist at Tergus Pharma leading a team with a focus towards development of various Topical dosage forms in branded NCE and complex Topical Generic formulations. He is an expert in materializing the design of experiments, QbD and in the development of the strategies for biowaiver during the development of formulations.
He has over 10 years of experience in formulation and development of 505(b)(2) and complex generics (ANDA), having been associated with Dermatology R&D, Dr. Reddys Laboratories and Martindale Pharma.
Srikanth Manne obtained his Masters in Industrial Pharmaceutics from University of Greenwich and Bachelors in Pharmacy from India.
Renee Daniels leads Talent Acquisition at Tergus Pharma, working closely with the executive leadership team aligning Talent Strategy with Human Resources. Renee is a results driven professional focused on promoting a positive company culture, strong employer brand, and solving tough hiring needs with creative, innovative solutions. Prior to joining Tergus Renee spent several years recruiting for companies such as IBM, GSK, and BD, working for the past 10 years at bioMerieux leading their Talent Acquisition team, supporting Change Management, Team Development and Coaching.
Renee graduated Virginia Tech with a Bachelor of Science (BS) degree, and is currently attending UNC Kenan-Flagler Business School as a 2020 MBA candidate. Renee is an active member of SHRM and has a Professional Recruitment Certification.